作者: Ismail Essadi , Hassan Errihani , Saber Boutayeb , El Mehdi Tazi , Hind
DOI: 10.4021/GR.V4I4.335
关键词:
摘要: The use of adjuvant chemotherapy has improved survival in early-stage colon cancer. Ongoing clinical trials are evaluating the addition targeted therapies to standard regimen. Preliminary results with bevacizumab were disappointing. Also, cetuximab added does not seem be better than alone, even selected wild-type KRAS populations. A understanding mechanisms action drugs, tumor biology, and predictive biomarkers needed design future trials.